

AstraZeneca

08:35 03 Jun 2019

AstraZeneca reports positive results from trial of pancreatic cancer treatment

AstraZeneca PLC (LON:AZN) said its Lynparza treatment nearly doubled the life-span of patients with metastatic pancreatic cancer in a phase III trial.

The trial tested Lynparza tablets as an initial maintenance treatment for metastatic pancreatic cancer patients, whose disease had not progressed after chemotherapy.

READ: AstraZeneca gets US regulatory green light for slow-release diabetes drug

Results showed "statistically significant and clinically meaningful improvement" in the time patients could live without their disease getting worse by an average of 7.4 months on Lynparza, compared to 3.8 months for those on placebo.

More than twice as many patients showed no disease progression both at one year and two years after starting to take Lynparza.

José Baselga, executive vice president of oncology research and development, said: "These unprecedented results raise new hope for patients that have seen little progress over a long period of time."

He said AstraZeneca is now working with regulatory authorities to bring Lynparza to patients "as quickly as possible".

Pancreatic cancer has the worst survival rate of the most common cancers with less than 3% of patients surviving more than five years after diagnosis.

Early diagnosis of pancreatic cancer is difficult because there are usually no symptoms until it is too late. About 80% of patients are diagnosed at the metastatic stage.

In 2018, there were 458,918 new cases of pancreatic cancer worldwide.

Price: 7314

Market Cap: £96.1 billion

1 Year Share Price Graph



Share Information

Code: AZN

Listing: LSE

52 week High Low
8227.88 109.511

Sector: Pharma & Biotech

Website: www.astrazeneca.com

Company Synopsis:

AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 employees and operates in over 100 countries with growing presence in important emerging markets.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability,

value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.